Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / MBRX - Moleculin Biotech rockets 115% premarket on potential COVID-19 treatment


MBRX - Moleculin Biotech rockets 115% premarket on potential COVID-19 treatment

  • Nano cap Moleculin Biotech (NASDAQ:MBRX) announces the results of in vitro testing in Germany showing that 2-deoxy-D-glucose (2-DG) totally stopped the replication of the SARS-CoV-2 virus. Specifically, researchers at the University of Frankfurt reported that inhibiting glycolysis (sugar metabolism) with non-toxic concentrations of 2-DG prevented the coronavirus from replicating in cell culture. 2-DG inhibits glycolysis because it is a decoy that cannot be converted into energy.
  • More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move,
  • Read more ...
Stock Information

Company Name: Moleculin Biotech Inc.
Stock Symbol: MBRX
Market: NASDAQ
Website: moleculin.com

Menu

MBRX MBRX Quote MBRX Short MBRX News MBRX Articles MBRX Message Board
Get MBRX Alerts

News, Short Squeeze, Breakout and More Instantly...